ONCOLOGY · LUNG CANCER
NSCLC pneumonitis and ILD observational study
Prospective research following patients beginning approved therapies.
Study overview
This prospective, multicenter observational study follows people with non-small cell lung cancer in the United States who are receiving standard care and beginning an approved treatment associated with a risk of pneumonitis or interstitial lung disease, also called ILD. Observational research records health information without assigning participants to an experimental treatment. Care decisions remain with each patient and treating clinician.
What researchers are examining
Researchers aim to better understand how pneumonitis and ILD are identified and managed during routine cancer care. These conditions involve inflammation or injury in lung tissue and may cause symptoms such as new or worsening cough, shortness of breath, chest discomfort, or fatigue. Study activities may include reviewing medical history, treatment information, symptoms, clinical assessments, imaging, laboratory results, and outcomes documented during regular visits. Exact procedures and follow-up timing are defined by the protocol.
Considering participation
Eligibility may depend on the type and stage of lung cancer, the approved therapy being started, prior treatments, current health, and other protocol requirements. Enrollment availability can change. Screening does not guarantee enrollment, and contacting California Research Institute does not obligate anyone to participate.
Participation is voluntary. The research team explains what information will be collected, expected follow-up, privacy protections, possible burdens, and participant rights before consent. Participants should promptly report new breathing symptoms to their treating clinician or follow the urgent-care instructions provided by their medical team.
For current information, call (323) 660-6200 or email trials@caresinst.org. Please do not email medical records or sensitive health details. This page is educational and does not replace medical advice.
The coordinator can explain current availability and initial screening.